Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
IRD
IRD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IRD News
Opus Genetics Reports 29.2% Revenue Growth in FY 2025
18h ago
seekingalpha
Opus Genetics Reports Positive Clinical Data for OPGx-BEST1 Therapy
Feb 27 2026
Newsfilter
Opus Genetics Receives FDA Review for New Drug Application
Feb 25 2026
Newsfilter
Opus Genetics Plans to Raise $25M in Private Placement
Feb 13 2026
seekingalpha
Opus Genetics Secures $25 Million in Private Placement Financing
Feb 13 2026
Newsfilter
Opus Genetics Insider Cam Gallagher Acquires 164,000 Shares of IRD for $323,693
Jan 02 2026
NASDAQ.COM
Opus Genetics Grants 50,000 Stock Options to Attract New Employee
Dec 16 2025
Globenewswire
Opus Genetics CEO to Present at J.P. Morgan 2026 Healthcare Conference on January 15, 2026
Dec 11 2025
Globenewswire
Opus Genetics CEO to Present at J.P. Morgan 2026 Healthcare Conference on January 15, 2026
Dec 11 2025
Newsfilter
Opus Genetics Advances as Eye Disease Research Continues Unchanged
Dec 09 2025
SeekingAlpha
Opus Genetics Advances BEST1 Clinical Trial as First Participant Shows Positive Safety Results
Dec 09 2025
Newsfilter
Opus Genetics Grants 124,000 Stock Options to Attract New Employees
Dec 02 2025
Globenewswire
Opus Genetics Approves 124,000 Stock Options as Employee Incentives
Dec 02 2025
Newsfilter
Top Analysts Recommend Purchasing These 3 Penny Stocks Immediately
Nov 21 2025
TipRanks
Opus Genetics Begins Dosing First Participant in Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Best Disease
Nov 13 2025
Newsfilter
Opus Genetics, Inc. Reports Q3 Loss That Falls Short of Expectations
Nov 12 2025
NASDAQ.COM
Show More News
